Atria Investments Inc Grows Holdings in Qiagen (NYSE:QGEN)

Atria Investments Inc lifted its stake in shares of Qiagen (NYSE:QGEN) by 6.0% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 7,632 shares of the company’s stock after purchasing an additional 433 shares during the period. Atria Investments Inc’s holdings in Qiagen were worth $348,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of the company. TD Asset Management Inc acquired a new stake in Qiagen in the second quarter worth $2,103,000. Raymond James & Associates lifted its stake in Qiagen by 12.7% during the second quarter. Raymond James & Associates now owns 542,453 shares of the company’s stock valued at $22,289,000 after purchasing an additional 61,008 shares during the last quarter. Barings LLC acquired a new position in shares of Qiagen in the 2nd quarter worth $12,463,000. Sei Investments Co. boosted its position in shares of Qiagen by 19.7% in the 2nd quarter. Sei Investments Co. now owns 1,696,319 shares of the company’s stock valued at $69,702,000 after purchasing an additional 278,930 shares during the period. Finally, Sycomore Asset Management purchased a new position in Qiagen in the 2nd quarter worth about $4,425,000. Institutional investors own 70.00% of the company’s stock.

Qiagen Trading Up 0.6 %

NYSE QGEN opened at $42.33 on Friday. The company has a current ratio of 2.17, a quick ratio of 1.89 and a debt-to-equity ratio of 0.39. Qiagen has a 1-year low of $39.03 and a 1-year high of $47.44. The firm’s fifty day simple moving average is $43.57 and its 200-day simple moving average is $43.73. The company has a market capitalization of $9.66 billion, a PE ratio of 108.38, a price-to-earnings-growth ratio of 3.16 and a beta of 0.41.

Analysts Set New Price Targets

QGEN has been the subject of several recent analyst reports. Robert W. Baird raised their target price on shares of Qiagen from $49.00 to $52.00 and gave the stock an “outperform” rating in a report on Friday, August 2nd. HSBC cut shares of Qiagen from a “buy” rating to a “hold” rating and set a $49.00 price objective on the stock. in a research report on Thursday, October 17th. Finally, Hsbc Global Res upgraded Qiagen to a “hold” rating in a report on Thursday, October 17th. Four research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $50.88.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.